AI Article Synopsis
- A young man was admitted to a medical center with shortness of breath and high troponin levels, following his first dose of the BioNTech mRNA vaccine.
- He was diagnosed with giant cell myocarditis and received immunosuppressive treatment.
- The report discusses the rare occurrence of myocarditis post-mRNA vaccination and the associated treatment strategies based on current guidelines.
Article Abstract
Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work-up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context of myocarditis after mRNA vaccination we discuss this rare aetiology and the patient's treatment strategy in the light of current recommendations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350328 | PMC |
| http://dx.doi.org/10.1002/ejhf.2590 | DOI Listing |
Publication Analysis
Top Keywords
giant cell
8
cell myocarditis
8
patient received
8
myocarditis dose
4
dose bnt162b2
4
bnt162b2 case
4
case report
4
report report
4
report case
4
case young
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!